Sanofi-aventis

Sanofi

Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt.

Richter Gedeon Nyrt.

Imre Bata

Sandor Batori

Lajos T Nagy

Zoltan Kapui

Katalin Urban-Szabo

Tibor Szabo

Peter Aranyi

Philippe Bovy

Edit Susan

Marton Varga

Eva Boronkay

Laszlo Balazs

Karoly Kanai

Veronika Bartane Bodor

Endre Mikus

Sándor Bátori

Zsuzsanna Tomoskozi

Katalin Urbán-Szabó

Zoltán Kapui

László Balázs

Gyorgy Ferenczy

Attila Vasas

Gabor Kovacs

Sandor Virag

Dezso Korbonits

Marcel Patek

Pal Kiss

Laszlo Tardos

Katalin Marmarosi Nee Kellner

Martin Smrcina

Gyula Papp

Peter S Kormoczy

Vera Gergely

Aleksandra Weichsel

Laszlo Szekeres

Péter Buzder-Lantos

Gabor Szeleczky

Tibor Szabó

Krisztina Vukics

David Squire Thorpe

Zsuzsanna Szamosvölgyi

Ferenc Baska

Zoltan Vargai

Péter Arányi

Geza Tímári

Kinga Boér

Mária Balogh

Eva Udvari

Márton Varga

Olivier Finance

Gábor Szeleczky

Éva Bozó

Krisztina Szondiné Kordás

Agnes Behr

Éva Boronkay

Edit Susán

Peter Arányi

Lászlo Balazs

Géza Timari

Péter Aranyi

Lászlö Balazs

Sándor Batori

Katalin Urbán Szabó

Ágnes Pappné Behr

Zoltán Szlávik

Veronika Bartáné Bodor

Gábor Szeleczki

Péter Budzer-Lantos

Zsuzsanna TÖMÖSKÖZI

Veronika BARTÁNÉ Bodor

György Ferenczy

David STHORPE

The present invention relates to 5,6-dihydro-4H-[1,2,4]triazolo[4,3-a][1]benzazepine derivatives of general formula (I) and/or salts thereof and/or geometric isomers thereof and/or stereoisomers thereof and/or enantiomers thereof and/or racemates thereof and/or diastereomers thereof and/or biologically active metabolites thereof and/or prodrugs thereof and/or solvates thereof and/or hydrates thereof and/or polymorphs thereof which are centrally and/or peripherally acting V1a receptor modulators, particularly V1a receptor antagonists. Additional subject of the present invention is the process for the preparation of the compounds and the intermediates of the preparation process as well. The invention also relates to the pharmaceutical compositions containing the compounds or together with one or more other active substances, as well as to the use in the treatment and/or prophylaxis of a disease or condition associated with V1a receptor function. 

Triazolobenzazepines as vasopressin V1a receptor antagonists

The present invention relates to compounds of formula 1 that are useful for the preventive and/or therapeutic treatment of diseases caused by abnormal activation of CXCR3 chemokines. The invention relates furthermore to a process for the preparation of said compounds, to pharmaceutical compositions containing said compounds and to novel intermediates used in the preparation of said compounds.

Substituted B-amino acid derivatives as CXCR3 receptor antagonists

The present invention relates to compounds of formula 1 that are useful for the preventive or therapeutic treatment of diseases caused by abnormal activation of CXCR3 chemokines. The invention relates furthermore to a process for the preparation of said compounds, to pharmaceutical compositions containing said compounds and to novel intermediates used in the preparation of said compounds.

Cycloalkane carboxylic acid derivatives as CXCR3 receptor antagonists

The present invention relates to pyrrolidinyl-alkyl-amide derivatives of formula (I) or (IA) wherein the variables are as defined herein, to their preparation and to their therapeutic use as CCR3 receptor ligands.

Pyrrolidinyl-alkyl-amide derivatives, their preparation, and their therapeutic application as CCR3 receptor ligands

The present invention relates to new, potent DPP-IV enzyme inhibitors of the general formula (I), which contain fluorine atoms.

Fluoropyrrolidines having dipeptidyl peptidase enzyme inhibitory activity

Heterocyclic amides useful as inhibitors of dipeptylpeptidase-IV (DPP-IV) enzyme, process for the preparation thereof and intermediates therefore.

Compounds

The present invention relates to the novel compounds of the general formula (I) possessing dipeptidyl peptidase IV enzyme inhibitory activity, pharmaceutical compositions thereof, methods of using said compounds, processes for their preparation and intermediates of the general formulae (II), (IV), (V), (VII), (VIII) and (IX).

Compounds useful for DPP-IV enzyme inhibition

Compounds of general formula (I), wherein Rand Rstand for hydrogen atom or form together an 1,3-butadienyl group, optionally substituted by a methylenedioxy group or one or more straight or branched Calkyl group, straight or branched Calkoxy group, hydroxy group or halogen atom; are strong adenosine Areceptor ligands preferably antagonists.

Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands

The invention relates to novel diphenylpropylamine derivatives of the general formula (I). ##STR1## R.sup.1 stands for hydrogen or a methyl group; R.sup.2 stands for hydrogen, a methyl or n-decyl group;

Diphenkylpropylamines for the therapy of heart disease

Growing community of inventors

Budapest, Hungary

Imre Bata